We have previously demonstrated that mGluR5 blockade inhibits translation of AβPP in synaptoneurosomes [11] and herein demonstrate reversion of several FXS phenotypes by genetic manipulation to reduce AβPP/Aβ. The gene discussed is GRM5; the disease is fragile X syndrome.